With COVID-19 forcing many rheumatologists to conduct consultations online, in Part 3 of our ACR 2020 highlights, Peter C Taylor (University of Oxford, Oxford, UK) summarises the investigation into the PT-CDAI, a patient-reported clinical disease activity tool that could help in target-based care in the era of telemedicine.Â
The study entitled ‘Can a Clinical Disease Activity Index Based on Patient-Reported Joint Counts (PT-CDAI) Be Used to Inform Target-Based Care in Telemedicine?’ was presented at ACR Convergence 2020.
Other highlights in this series include PART 1, PART 2 and PART 4.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
